Ruxolitinib is an oral medication classified as a Janus kinase (JAK) inhibitor. It is primarily used to treat certain blood disorders, including myelofibrosis and polycythemia vera, by reducing abnormal blood cell production and alleviating symptoms such as spleen enlargement and fatigue. Ruxolitinib is available in various strengths and should be used under the guidance of a healthcare professional, with dosage tailored to the individual patient based on their specific medical condition and response to treatment.